GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
GSK shares surge around 6% as drugmaker raises sales target and boosts dividends
Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and ...
GSK lifts long-term sales targets on new drug pipeline
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
Arizona says GlaxoSmithKline's greed endangered kids with asthma
GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...
GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
Key Takeaways GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and ...
GSK launches £2bn buyback on strong HIV and cancer drugs sales
GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines, ...
Fierce Pharma4d
Will Gilead's twice-yearly injection dominate the HIV PrEP market? GSK doesn’t think so
The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...
GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook
The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...
GSK Reported Strong Earnings, So I Reiterate My Strong Buy
GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...
Rapid trials prompt deals rush for Chinese ‘super me-too’ drugs
Western drugmakers are striking more deals in China to access “bio-better” treatments for diseases from obesity to cancer, ...
Fierce Pharma5d
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Yahoo Finance5d
GSK Lifts Long-Term Outlook on Drug Pipeline, Buys Back Shares
(Bloomberg) -- GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline. The British drugmaker boosted its 2031 ...